Parabilis Medicines Reports Third Quarter 2026 Financial Results and Provides Business Updates
Presented updated Phase 1/2 data at ESMO Congress 2026 demonstrating a 72.2% objective response rate
Presented updated Phase 1/2 data at ESMO Congress 2026 demonstrating a 72.2% objective response rate